Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

ATLAS Biolabs is Awarded Certified Service Provider Accreditation from Affymetrix for DMET Analysis

Published: Tuesday, September 25, 2012
Last Updated: Tuesday, September 25, 2012
Bookmark and Share
DMET Plus uses microarray testing to investigate common variations in genes encoding for drug-metabolism enzymes and drug transporters, and to identify their impact on the individual metabolic capacity.

ATLAS Biolabs announces its accreditation as a certified Affymetrix DMET™ Service Provider, offering the latest DMET™ Plus Solution from Affymetrix. ATLAS Biolabs is the first European Certified Service Provider to offer the DMET technology for use in molecular pharmacogenetics in Germany.

Allelic variants with catalytic activities different from wild-type forms have been identified for an increasing number of drug-metabolizing enzymes and drug transporters. Analyzing the diversity of these proteins has become extremely important in the evaluation of drug toxicity. Thus, genotyping patients with respect to a particular genetic variant helps to avoid adverse drug responses, increase treatment efficacy, and achieve both improved healthcare outcomes and substantial economic benefits.

DMET Plus covers a broad range of 1,936 genetic variants across 231 relevant genes in one assay. Moreover, the test inspires high confidence in results and supports the rapid and comprehensive interpretation of genotyping data. DMET Plus will be useful in the discovery of novel biomarkers resulting from pharmacogenetic associations, as well as in the optimization of drug candidates. DMET could also improve translational and clinical trials by showing the effects of known metabolic pathways in poor drug responders, and confirm metabolic pathway involvement in newly discovered drug-metabolism associations.

“DMET helps translate pharmacogenetics into practice and will take us one step closer to the vision of personalized medicine,” says Patrick Kelly, Director of Sales and Market Development at ATLAS Biolabs. “We are excited to offer our customers this new tool, which opens up the possibility of measuring existing and new metabolic pathways in a cost-effective and very reliable way.”

The DMET™ Plus Solution
DMET Plus from Affymetrix includes (a) a molecular inversion probe (MIP) panel to amplify the precise target DNA of interest; (b) an allele-specific oligonucleotide array providing a single-color readout on Affymetrix’s GeneChip System® 3000 or the GeneChip® System 3000Dx v.2; and (c) the DMET analysis software, which offers both flexibility for user-defined reporting and the most comprehensive translation from genotypic data to star-allele classification and to predicted metabolizer status for the most clinically relevant genes. Assay performance is characterized by >99% average sample-call rates and >99.8% average sample reproducibility, which enables the accurate generation of haplotypes and supports longitudinal and other clinical research studies.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Four New Genetic Disorders Identified
Sharing of genetic data empowers discovery of new disorders in children.
Biomarker Predicting Transplant Complications May be Key to Treating Them
A protein that can be used to predict if a stem cell transplant patient will suffer severe complications may also be the key to preventing those complications, an international research team based at the Indiana University School of Medicine reported Wednesday.
Potential New Diagnosis and Therapy for Breast Cancer
Scientists at the University of York, using clinical specimens from charity Breast Cancer Now’s Tissue Bank, have conducted new research into a specific sodium channel that indicates the presence of cancer cells and affects tumour growth rates.
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos